×
About 855 results

ALLMedicine™ Carcinoid Tumor Center

Research & Reviews  314 results

Natural History of Familial Carcinoid Tumor
https://clinicaltrials.gov/ct2/show/NCT00646022

May 20th, 2022 - Study Description: This study is designed as a prospective evaluation for diagnostic screening, genotyping and natural history of participants belonging to kindreds with familial carcinoid tumor. Objectives: Primary Objective: Study the natural hi...

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
https://clinicaltrials.gov/ct2/show/NCT03375320

May 20th, 2022 - PRIMARY OBJECTIVES: I. To determine whether cabozantinib S-malate (cabozantinib) can significantly improve progression-free survival (PFS) compared to placebo in patients with advanced pancreatic neuroendocrine tumors (NET) whose disease has progr...

Single-incision port robot-assisted surgery for thymic carcinoid tumor resection.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066919
Journal of Cardiothoracic Surgery; Shidei H, Mitsuboshi S et. al.

May 4th, 2022 - Multiple endocrine neoplasia (MEN) is divided into MEN type 1 (MEN-1) and MEN type 2 (MEN-2). MEN-1 may be associated with thymic carcinoid tumors. We present a case of the surgical removal of a thymic carcinoid associated with MEN-1 via a single-...

Pancreatic Carcinoid Tumor in a Pediatric Patient.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003623
The American Journal of Case Reports; Musalli DI, Binafif YA et. al.

Apr 9th, 2022 - BACKGROUND Carcinoid tumors are well-differentiated tumors that develop from neuroendocrine cells. They are rare tumors and occur most commonly in the gastrointestinal tract, followed by the pulmonary system. They usually present with abdominal pa...

MEN4, the MEN1 mimicker; a case series of 3 phenotypically heterogenous patients with u...
https://doi.org/10.1210/clinem/dgac162
The Journal of Clinical Endocrinology and Metabolism; Seabrook A, Wijewardene A et. al.

Mar 25th, 2022 - Germline CDKN1B pathogenic variants result in Multiple Endocrine Neoplasia type 4, an autosomal dominant hereditary tumor syndrome variably associated with primary hyperparathyroidism, pituitary adenoma and duodenopancreatic neuroendocrine tumors....

see more →

Clinicaltrials.gov  8 results

Natural History of Familial Carcinoid Tumor
https://clinicaltrials.gov/ct2/show/NCT00646022

May 20th, 2022 - Study Description: This study is designed as a prospective evaluation for diagnostic screening, genotyping and natural history of participants belonging to kindreds with familial carcinoid tumor. Objectives: Primary Objective: Study the natural hi...

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
https://clinicaltrials.gov/ct2/show/NCT03375320

May 20th, 2022 - PRIMARY OBJECTIVES: I. To determine whether cabozantinib S-malate (cabozantinib) can significantly improve progression-free survival (PFS) compared to placebo in patients with advanced pancreatic neuroendocrine tumors (NET) whose disease has progr...

Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
https://clinicaltrials.gov/ct2/show/NCT01782443

Jun 22nd, 2021 - If you are willing to participate in this study you will be asked to undergo some screening tests and procedures to confirm that you are eligible. Many of these tests and procedures are likely to be part of regular cancer care and may be done even...

Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
https://clinicaltrials.gov/ct2/show/NCT01548482

Oct 6th, 2015 - PRIMARY OBJECTIVES: I. To determine the recommended phase II dose (RP2D) and safety profile of AMG 386 (trebananib) in combination with temsirolimus in patients with advanced solid tumors. SECONDARY OBJECTIVES: I. To evaluate pharmacodynamic (PD) ...

The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis
https://clinicaltrials.gov/ct2/show/NCT01496196

Apr 14th, 2015 - Hemoptysis is defined as the expectoration of blood from respiratory tract, a spectrum that varies from blood-streaking of sputum to coughing up large amounts of pure blood. Massive hemoptysis variably defined as the expectoration of 100-600 ml ov...

see more →

News  18 results

Exceptional Responder Provides Treatment Clues in Bladder Cancer
https://www.onclive.com/view/exceptional-responder-provides-treatment-clues-in-bladder-cancer

Oct 6th, 2021 - Nikhil Wagle, MD An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib (Votrient), according to r...

Pralsetinib Elicits Durable Anti-Tumor Effects in RET Fusion+ Solid Tumors
https://www.onclive.com/view/pralsetinib-elicits-durable-anti-tumor-effects-in-ret-fusion-solid-tumors

Jun 5th, 2021 - Pralsetinib (Gavreto) demonstrated robust and durable anti-tumor activity, as well as a tolerable safety profile, in heavily pretreated patients with multiple RET fusion–positive advanced solid tumors, according to updated findings from the ARROW ...

Role of Somatostatin Analogs for Patients With pNETs
https://www.onclive.com/view/role-of-somatostatin-analogs-for-patients-with-pnets

Apr 2nd, 2021 - For High-Definition, Click Somatostatin analogs, which have historically been used to control hormone symptoms, recently demonstrated antiproliferative activity for patients with neuroendocrine tumors, states Matthew H. Kulke, MD. This activity ...

SPINET Trial Could Alter Practice for Patients With Lung NETs
https://www.onclive.com/view/spinet-trial-could-alter-practice-for-patients-with-lung-nets

Dec 20th, 2020 - Diane Reidy-Lagunes, MD Since its FDA approval in 2014, the somatostatin analog lanreotide (Somatuline Depot) has been creating fresh options for select patients with gastroenteropancreatic neuroendocrine tumors (NETs), given the significant impr...

Novel Drug Relieves Carcinoid Syndrome Symptoms
https://www.onclive.com/view/novel-drug-relieves-carcinoid-syndrome-symptoms

Dec 20th, 2020 - Matthew H. Kulke, MD Telotristat etiprate, a novel serotonin synthesis inhibitor, helped reduce daily bowel movements for patients with carcinoid syndrome no longer responding to standard-of-care therapies, an encouraging signal for an emerging c...

see more →

Patient Education  2 results see all →